On Nov. 6, 2025, Novo Nordisk announced it has agreed with the U.S. Administration to lower drug prices beginning in 2026 and expand patient access and affordability for semaglutide medicines, including Wegovy^® and Ozempic^®, in U.S. Medicare Part D and Medicaid and in direct-to-patient cash channel.

Medicare Part D coverage for anti-obesity medicines will be enabled through a pilot program designed to cover a majority of Part D beneficiaries. In addition, Novo Nordisk is expected to receive a three-year tariff exemption.

Novo Nordisk currently expects an estimated direct, negative low single-digit impact on global sales growth in 2026. Implementation is expected to begin in 2026.

The forward-looking statements section on page 28 in the financial report for the first nine months of 2025 (Company Announcement No 31/2025) also apply to this company announcement. Novo Nordisk is expected to provide the financial outlook for 2026 in connection with the announcement of the full-year 2025 results on 4 February 2026.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.